Foghorn therapeutics provides third quarter 2021 corporate update

-- first patient dosed in phase 1 clinical trial of fhd-609, a potent and selective heterobifunctional protein degrader of brd9, initially being developed for the treatment of synovial sarcoma
FHTX Ratings Summary
FHTX Quant Ranking